AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30070045 — intervention group
Group type: COMPARATOR
Intervention: No weighing (excluded from analysis)
Number of subjects: 0
Study 28032918 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery Program (IMR) for 12 months
Number of subjects: 50
Study 28032918 — intervention group
Group type: COMPARATOR
Intervention: Standard care management by community psychiatric nurses for 12 months
Number of subjects: 50
Study 25994742 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombectomy (using the Export catheter, Medtronic Cardiovascular)
Number of subjects: 214
Study 25994742 — intervention group
Group type: COMPARATOR
Intervention: PCI-alone
Number of subjects: 214
Study 25994742 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombectomy
Number of subjects: 214
Study 25994742 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombectomy and PCI-alone
Number of subjects: 214
Study 23940461 — intervention group
Group type: COMPARATOR
Intervention: Viral load (VL) monitoring
Number of subjects: 716
Study 23940461 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 monitoring
Number of subjects: 716
Study 23940461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monitoring strategies
Number of subjects: 716
Study 22024492 — intervention group
Group type: COMPARATOR
Intervention: General low fat (LF) control
Number of subjects: 122
Study 22024492 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured LF high polyunsaturated fat (PUFA) (LF-PUFA)
Number of subjects: 122
Study 18806734 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent vaccine Pneumovax (0.5 mL administered intramuscularly)
Number of subjects: 51
Study 16860190 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment (50 U/kg/wk) for 12 months
Number of subjects: 88
Study 16860190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment until hemoglobin < 9 g/dL)
Number of subjects: 88
Study 16860190 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 88
Study 14585521 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 50 microg/day
Number of subjects: 0
Study 14585521 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot 100 microg/day
Number of subjects: 0
Study 14585521 — intervention group
Group type: COMPARATOR
Intervention: Menorest 100 microg/day
Number of subjects: 0
Study 14585521 — intervention group
Group type: COMPARATOR
Intervention: Menorest 50 microg/day
Number of subjects: 0
Study 14585521 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot
Number of subjects: 0
Study 14585521 — intervention group
Group type: COMPARATOR
Intervention: Menorest
Number of subjects: 0
Study 11061459 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone plug
Number of subjects: 120
Study 11061459 — intervention group
Group type: COMPARATOR
Intervention: Open entry point
Number of subjects: 120
Study 9375594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 2.5 mg p.o. t.i.d. for 2 weeks
Number of subjects: 10
Study 9375594 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 10
Study 8330544 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oxygen at 4 liters/minute through nasal cannulae
Number of subjects: 200
Study 8330544 — intervention group
Group type: COMPARATOR
Intervention: No additional oxygen
Number of subjects: 200
Study 8330544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam or diazepam suspension
Number of subjects: 200
Study 3033968 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia with DA premedication (diazepam 0.25 mg kg‐1 and atropine 0.015 mg kg‐1)
Number of subjects: 48
Study 3033968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 48
Study 3033968 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 48
Study 3033968 — intervention group
Group type: EXPERIMENTAL
Intervention: DMS premedication (diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1, scopolamine 0.01 mg kg‐1)
Number of subjects: 48
Study 3033968 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 48
Study 3033968 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, enflurane, isoflurane anaesthesia
Number of subjects: 48
Study 29609475 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Condition (EC) - smartphone-based worry-reduction training with mindfulness exercises
Number of subjects: 136
Study 29609475 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC) - registered emotions five times daily for four weeks
Number of subjects: 136
Study 29609475 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Condition (WL) - not specified in detail
Number of subjects: 136
Study 26971032 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of voice
Number of subjects: 0
Study 24297796 — intervention group
Group type: COMPARATOR
Intervention: hCG supplementation 0 IU/d (D0)
Number of subjects: 62
Study 24297796 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation 50 IU/d (D50)
Number of subjects: 62
Study 24297796 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation 100 IU/d (D100)
Number of subjects: 62
Study 24297796 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation 150 IU/d (D150)
Number of subjects: 62
Study 22762251 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech TiOblast implants
Number of subjects: 46
Study 22762251 — intervention group
Group type: COMPARATOR
Intervention: Brånemark turned implants
Number of subjects: 46
Study 21181638 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 24
Study 21181638 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study 18462354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosufloxacin (300 mg twice daily for 2 days, initial dose 2 hours prior to biopsy)
Number of subjects: 243
Study 18462354 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (200 mg twice daily for 2 days, initial dose 2 hours prior to biopsy)
Number of subjects: 243
Study 17143240 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-ICP measurement
Number of subjects: 27
Study 17143240 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal MR-ICP value
Number of subjects: 27
Study 12713277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% itraconazole cream, 5 g application
Number of subjects: 0
Study 12713277 — intervention group
Group type: EXPERIMENTAL
Intervention: HPbetaCD-based, emulsified wax cream formulation
Number of subjects: 0
Study 12713277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% itraconazole cream
Number of subjects: 0
Study 10934081 — intervention group
Group type: EXPERIMENTAL
Intervention: rPAF‐AH (1 mg/kg)
Number of subjects: 14
Study 10934081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8742212 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute session with a clinic nurse including an educational booklet and follow-up telephone call
Number of subjects: 293
Study 8742212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293
Study 8742212 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 293
Study 1312588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 1.5 mg/m2
Number of subjects: 30
Study 1312588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 2.0 mg/m2
Number of subjects: 30
Study 1312588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 2.5 mg/m2
Number of subjects: 30
Study 1312588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (all doses)
Number of subjects: 30
Study 6397365 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified semi-synthetic human insulin
Number of subjects: 24
Study 6397365 — intervention group
Group type: COMPARATOR
Intervention: Highly purified porcine insulin
Number of subjects: 24
Study 31203685 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5% plus breast milk
Number of subjects: 51
Study 31203685 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5% plus sucrose 24%
Number of subjects: 51
Study 31203685 — intervention group
Group type: COMPARATOR
Intervention: Proparacaine HCl ophthalmic solution 0.5%
Number of subjects: 51
Study 31203685 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 51
Study 31203685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose group
Number of subjects: 51
Study 29672196 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (twice a day for three months)
Number of subjects: 46
Study 29672196 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 46
Study 29672196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29351139 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (standard care + PPCC)
Number of subjects: 130
Study 29351139 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 130
Study 27185033 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal grafting (EG)
Number of subjects: 0
Study 27185033 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin grafting (SSG)
Number of subjects: 0
Study 25388622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HAM flour cookie (33% wheat flour, 67% HAM flour)
Number of subjects: 30
Study 25388622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HAM flour cookie (63% wheat flour, 37% HAM flour)
Number of subjects: 30
Study 25388622 — intervention group
Group type: COMPARATOR
Intervention: Control cookie (100% wheat flour)
Number of subjects: 30
Study 23659987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine therapy
Number of subjects: 498
Study 19730258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 70
Study 19730258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18434437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT): 6 weeks, 4-6 sessions per week, each session consisting of four to six 30-second 'all-out' Wingate tests with 4.5 minutes of recovery between tests
Number of subjects: 20
Study 18434437 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET): 6 weeks, 5 sessions per week, each session consisting of 40-60 minutes of cycling at 65% of peak oxygen uptake (Vo2peak)
Number of subjects: 20
Study 18434437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 15690267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block with propofol infusion
Number of subjects: 105
Study 15690267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine 1 mg/kg
Number of subjects: 105
Study 15690267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 2 microg/kg
Number of subjects: 105
Study 12826215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2000 mg/d, CSA tapered to trough levels of 70 to 120 microg/L
Number of subjects: 14
Study 12826215 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained on CSA dosages and azathioprine (AZA)
Number of subjects: 14
Study 10499601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needle injection of rV-CEA (10^7 or 10^8 pfu)
Number of subjects: 20
Study 10499601 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous jet administration of rV-CEA (10^7 or 10^8 pfu)
Number of subjects: 20
Study 10499601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (intradermal and subcutaneous)
Number of subjects: 20
Study 10499601 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous jet injection of rV-CEA
Number of subjects: 20
Study 10499601 — intervention group
Group type: EXPERIMENTAL
Intervention: 10^8 pfu doses of rV-CEA
Number of subjects: 20
Study 10499601 — intervention group
Group type: EXPERIMENTAL
Intervention: rV-CEA vaccine
Number of subjects: 20
Study 7700310 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma patients (AIDS-associated, classic, and HIV-negative homosexual men)
Number of subjects: 21
Study 7700310 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study 7700310 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninvolved skin samples from Kaposi's sarcoma patients
Number of subjects: 21
Study 1698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Road-to-health (RTH) chart
Number of subjects: 1221
Study 1698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth surveillance (GS) chart
Number of subjects: 1221
Study 1698566 — intervention group
Group type: COMPARATOR
Intervention: No chart (control)
Number of subjects: 1221
Study 756473 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat messages
Number of subjects: 182
Study 756473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threat messages
Number of subjects: 182
Study 756473 — intervention group
Group type: COMPARATOR
Intervention: Control (no communication)
Number of subjects: 182
Study 756473 — intervention group
Group type: EXPERIMENTAL
Intervention: General beliefs concerning health and specific beliefs about obesity and dieting
Number of subjects: 182
Study 31005497 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 78
Study 31005497 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout intervention
Number of subjects: 78
Study 31005497 — intervention group
Group type: EXPERIMENTAL
Intervention: Video+handout intervention
Number of subjects: 78
Study 31005497 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 78
Study 28253073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with fixed appliance; administered monthly using a Diode laser (980 nm, 1 W, continuous wave, total energy density = 150 J/cm2)
Number of subjects: 36
Study 28253073 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance only (control group)
Number of subjects: 36
Study 25891006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 60 mg/m2, thalidomide 100 mg, dexamethasone 20 mg
Number of subjects: 94
Study 25891006 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine 100 mg/m2
Number of subjects: 94
Study 23263772 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599506 with dose titration
Number of subjects: 0
Study 23263772 — intervention group
Group type: COMPARATOR
Intervention: LY2599506 with fixed dosing
Number of subjects: 0
Study 23263772 — intervention group
Group type: COMPARATOR
Intervention: LY2599506 (50-400 mg BID)
Number of subjects: 0
Study 20405185 — intervention group
Group type: EXPERIMENTAL
Intervention: No rubbing action
Number of subjects: 40
Study 20405185 — intervention group
Group type: EXPERIMENTAL
Intervention: Slight rubbing action
Number of subjects: 40
Study 20405185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous rubbing action
Number of subjects: 40
Study 19512949 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 242
Study 16722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete randomization
Number of subjects: 0
Study 16722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Urn randomization
Number of subjects: 0
Study 16722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive randomization
Number of subjects: 0
Study 16722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified schemes
Number of subjects: 0
Study 16722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstratified schemes
Number of subjects: 0
Study 15451764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 63
Study 15451764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 63
Study 15451764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 63
Study 15451764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10930358 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline (6 mg/kg in bolus and 1.2 mg/kg per h for maintenance)
Number of subjects: 43
Study 10930358 — intervention group
Group type: COMPARATOR
Intervention: Control Group (received nebulization with fenoterol and intravenous hydrocortisone)
Number of subjects: 43
Study 10930358 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline
Number of subjects: 43
Study 9298177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarosan (acaricide) applied on mattresses and textile floor coverings
Number of subjects: 59
Study 9298177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress encasings (allergen-impermeable)
Number of subjects: 59
Study 9298177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for acaricide)
Number of subjects: 59
Study 9298177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for mattress encasings)
Number of subjects: 59
Study 7688007 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (3 mU 3 times a week for 6 months)
Number of subjects: 65
Study 7688007 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group for elderly)
Number of subjects: 65
Study 3726509 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (2 X 800 micrograms daily)
Number of subjects: 12
Study 3726509 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalations
Number of subjects: 12
Study 31088335 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 538
Study 31088335 — intervention group
Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 538
Study 31088335 — intervention group
Group type: COMPARATOR
Intervention: Age-matched groups
Number of subjects: 538
Study 31088335 — intervention group
Group type: COMPARATOR
Intervention: Cox regression analysis
Number of subjects: 538
Study 29587572 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Transtheoretical Model Intervention (ETMI)
Number of subjects: 214
Study 29587572 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 214
Study 27178852 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 30
Study 27178852 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 30
Study 27178852 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine
Number of subjects: 30
Study 23987240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Number of subjects: 38
Study 23987240 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 38
Study 22154367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electroacupuncture (EA)
Number of subjects: 84
Study 22154367 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 84
Study 22154367 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 84
Study 20858275 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 247
Study 20858275 — intervention group
Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 247
Study 18288119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid supplementation at 3.5 g kg(‐1) per day, advanced by 1.0 g kg(‐1) per day to a maximum of 3.5 g kg(‐1) per day
Number of subjects: 122
Study 18288119 — intervention group
Group type: COMPARATOR
Intervention: Amino-acid supplementation at 2.5 g kg(‐1) per day, advanced by 0.5 g kg(‐1) per day to a maximum of 2.5 g kg(‐1) per day
Number of subjects: 122
Study 15996694 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% paired flavor
Number of subjects: 90
Study 15996694 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% paired flavor
Number of subjects: 90
Study 15996694 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% paired CS
Number of subjects: 90
Study 15996694 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% paired CS
Number of subjects: 90
Study 15996694 — intervention group
Group type: EXPERIMENTAL
Intervention: US devaluation
Number of subjects: 90
Study 12084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 97
Study 12084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple system atrophy (MSA)
Number of subjects: 97
Study 12084439 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 97
Study 12084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 97
Study 10337722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention agents
Number of subjects: 0
Study 10337722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing randomized phase III/IV chemoprevention trials
Number of subjects: 0
Study 8909485 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin use
Number of subjects: 3184
Study 1858481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent diazepam prophylaxis (few doses per year)
Number of subjects: 0
Study 1858481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute anticonvulsant treatment with rectal diazepam
Number of subjects: 0
Study 1858481 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 1858481 — intervention group
Group type: COMPARATOR
Intervention: Long-term prophylaxis with phenobarbital or valproate
Number of subjects: 0
Study 6628518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg/day
Number of subjects: 12
Study 6628518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg/day
Number of subjects: 12
Study 6628518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 250 mg/day
Number of subjects: 12
Study 6628518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1000 mg/day
Number of subjects: 12
Study 6628518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg/day for 14 days
Number of subjects: 12